EN DE
Watch LifeTech Scientific Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LifeTech Scientific Corp (1302) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of LifeTech Scientific Corp stock HK$1.70, price HK$1.55, upside +10.0%, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG548721177

LS LifeTech Scientific Corp logo Thin data Nov 14, 2026

LifeTech Scientific Corp

1302 · HK

Solid company, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Quality 68/100 
Low debt 
Generates free cash flow 
Fair value HK$1.70 · Fairly valued 
Mixed Growth (revenue 5y +16.4 %/yr in CNY) 
Thin margins · 4.5% net margin (TTM) 
Mixed vs. peers (7/13) 
Costs 154 times its yearly profit. 
Falling price (downtrend) 
Narrow moat 34/100 · thin data
Thin data 
Quality growth
Watch LifeTech Scientific Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$5.62 HK$1.26 Fair Value HK$1.70 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range HK$1.26 – HK$5.62 · fair‑value band HK$1.19 – HK$2.20 · the HK$1.55 price screens below the HK$1.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.

Follow LifeTech Scientific in your weekly email

Every Wednesday you see whether LifeTech Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally.

Show moreShow less

It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments.

It is also involved in biomedical research and development; properties leasing business; and developing, manufacturing, and trading of medical devices, as well as offers technical, consulting, and technology services.

LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, China.

Stock analysis

LifeTech Scientific Corp (1302) currently trades at HK$1.55, while our model-based Fair Value estimate is HK$1.70, so the stock looks roughly fairly valued today (gap 9.1%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$2.25 per share, and 10 of the 24 models we run sit above the HK$1.55 price.

Bear case: the Asset-Based group reads lowest at HK$0.2200, and 14 of the 24 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$1.19 (bear) to HK$2.20 (bull), the price of HK$1.55 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

LifeTech Scientific Corp reported revenue of 1.4B CNY in FY2025 versus 925M CNY in FY2021, a compound +10.3%/yr. Reported net income was 148M CNY in FY2025, compounding −15.7%/yr from FY2021.

Key figures

Market cap HK$6.8B (≈ $863M) Small · P/E ratio 154.0 · P/S ratio 16.6 · Net margin 10.8% · Return on equity 0.6% · Return on assets (EBIT) 7.2% (5-year average) · Operating margin 3.7% · Revenue (TTM) 1.3B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 10%, 1302 screens cheaper than that median.

Fair Value models

Bear HK$1.19 Fair Value HK$1.70 Bull HK$2.20
Price HK$1.55 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$1.72 HK$2.97 HK$5.90 76
Growth DCF HK$1.67 HK$3.07 HK$5.08 76
5Y EBITDA Exit HK$1.06 HK$1.74 HK$2.60 74
All 24 models by family
DCF Models
FCF DCF HK$1.72 HK$2.97 HK$5.90 76
Owner Earnings HK$0.9600 HK$1.80 HK$3.26 73
5Y Revenue Exit HK$0.9100 HK$1.41 HK$2.08 72
5Y EBITDA Exit HK$1.06 HK$1.74 HK$2.60 74
5Y P/E Exit HK$1.02 HK$1.65 HK$2.39 70
10Y Revenue Exit HK$1.17 HK$1.76 HK$2.65 66
10Y EBITDA Exit HK$1.28 HK$1.99 HK$3.10 67
10Y P/E Exit HK$1.25 HK$1.93 HK$2.92 63
Earnings-Based
Graham-Dodd HK$0.2700 HK$1.57 HK$2.19 63
Lynch FV HK$0.4400 HK$0.6400 HK$0.8300 61
PEG = 1.0 HK$0.4400 HK$0.6400 HK$0.8300 57
EPV HK$0.3000 HK$0.3300 HK$0.3600 74
Multiples
P/E Multiple HK$0.6500 HK$0.8700 HK$1.09 63
P/S Multiple HK$0.5000 HK$0.6700 HK$0.8400 58
P/B Multiple HK$2.46 HK$3.28 HK$4.11 55
EV/EBIT HK$0.8300 HK$1.04 HK$1.25 66
EV/EBITDA HK$0.9200 HK$1.15 HK$1.39 67
EV/Revenue HK$0.6500 HK$0.8500 HK$1.04 54
Asset-Based
NCAV (Graham) HK$0.1500 HK$0.2200 HK$0.2800 54
Growth DCF
Growth DCF HK$1.67 HK$3.07 HK$5.08 76
Rev-Margin DCF HK$0.9100 HK$1.42 HK$2.11 72
Economic Profit
Residual Income HK$0.6700 HK$0.6600 HK$0.6800 71
ROIC Compounder HK$0.3000 HK$0.3300 HK$0.3600 72
Growth Earnings
Growth-Adj P/E HK$0.6700 HK$0.9500 HK$1.24 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 32
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 98
Do the profits arrive as real cash?
Financial strength 89
Debt, balance sheet and risk of trouble
Investment 68
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 18
Distance to the 52-week high, does not count
New shares 88
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Start year 2020 (pandemic). Over 10 years: +16.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−7.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7.4% vs 6.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.41% → 14%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −3.1% a year for the price.

Watch 1302, get fair value alerts →

Compare LifeTech Scientific Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside +10.0% · Top 25%
Profitability
Return on equity (12 months) 0.6% · Above median
Return on assets 3.0% · Above median
Net margin (12 months) 4.5% · Above median
Operating margin (12 months) 3.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −11.2% · Bottom 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 154.0× · Priciest 25%
P/B 1.64× · Cheaper than median
P/S (12 months) 4.45× · Pricier than median
Price / free cash flow (fiscal year) 11.5× · Cheapest 25%
EV/EBITDA 18.9× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)47 · sector 16
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)3 · sector 0
HEALTH (low debt)92 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $343.63 +11% vs 1302
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs 1302
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 1302
DexCom, Inc DXCM $83.33 $91.66 +10% vs 1302
STERIS plc STE $264.32 $281.90 +7% vs 1302
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 1302
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 1302
Medtronic plc MDT $102.86 $74.90 −27% vs 1302
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 1302
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 1302

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LifeTech Scientific Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LifeTech Scientific Corp Fair Value". https://www.fairvalue-calculator.com/stock/1302

Frequently asked questions

Is LifeTech Scientific Corp (1302) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$1.70 versus a price of HK$1.55, about +10% upside (fairly valued).
What is the fair value of 1302?
Our model-based fair value for LifeTech Scientific Corp is HK$1.70 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$1.55.
What is the quality score of 1302?
LifeTech Scientific Corp has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LifeTech Scientific Corp (1302)?
Our model-based price target is the fair value of HK$1.70 (as of Nov 14, 2026) from 24 valuation models. Cautious scenario HK$1.19, optimistic scenario HK$2.20. It is a calculation from audited fundamentals, not an analyst target.
What is the LifeTech Scientific Corp stock forecast for 2026?
Our models put fair value at HK$1.70, about +10% upside versus a price of HK$1.55 (fairly valued). Cautious scenario HK$1.19, optimistic scenario HK$2.20. The calculation is refreshed regularly with new filings.
What is the revenue of LifeTech Scientific Corp (1302)?
LifeTech Scientific Corp reported trailing-twelve-month revenue of about 1.3B CNY (latest available figure, as of Nov 14, 2026).
What growth is priced into LifeTech Scientific Corp (1302)?
Today's price is already fair in a discounted-cash-flow model if free cash flow at LifeTech Scientific Corp shrinks by 1.4 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 16.4 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of 1302 use?
Our models discount LifeTech Scientific Corp at 10.3 %: a base by market capitalisation (small), damped by beta 0.31, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For LifeTech Scientific Corp that is -1.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has LifeTech Scientific Corp (1302) delivered so far?
Over the past 5 years revenue at LifeTech Scientific Corp grew 16.4 % a year. The price currently implies free-cash-flow growth of -1.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of LifeTech Scientific Corp (1302) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into LifeTech Scientific Corp (-1.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of LifeTech Scientific Corp (1302)?
The free-cash-flow yield on the price is 8.71 %: that much free cash flow LifeTech Scientific Corp produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of LifeTech Scientific Corp (1302)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LifeTech Scientific Corp it is HK$1.70 per share (as of Nov 14, 2026), against a price of HK$1.55. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is LifeTech Scientific Corp stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 1302 trades below its calculated fair value: price HK$1.55, fair value HK$1.70, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1302?
No. The price is what the market pays today (HK$1.55); the fair value is what the company's own numbers justify (HK$1.70). For LifeTech Scientific Corp the two are HK$0.1545 per share apart. That gap is exactly why we show both numbers side by side.
How much is LifeTech Scientific Corp worth?
The market values LifeTech Scientific Corp at about HK$6.8B (market capitalisation, as of Nov 14, 2026). Per share that is HK$1.55; our models calculate a fair value of HK$1.70 per share.
What do the bullish and bearish scenarios say about 1302?
Our models span a range for LifeTech Scientific Corp: cautious scenario HK$1.19, base HK$1.70, optimistic HK$2.20 per share (as of Nov 14, 2026, price HK$1.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1302?
LifeTech Scientific Corp trades at a price-to-earnings ratio of 154.0 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$1.70 is built from several models across several years. Other multiples: P/B 1.6, P/S 4.5, EV/EBITDA 18.9.
How solid is the balance sheet of LifeTech Scientific Corp (1302)?
Balance-sheet figures for LifeTech Scientific Corp (as of Nov 14, 2026): return on equity 0.6%, debt of 0.16 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is 1302 from its 52-week high?
LifeTech Scientific Corp trades at HK$1.55, about 33% below its 52-week high of HK$2.31 and 19% above the low of HK$1.30 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.70 is for.
Which stocks are comparable to LifeTech Scientific Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LifeTech Scientific Corp stock attractive at the current price?
The data as of Nov 14, 2026: price HK$1.55, calculated fair value HK$1.70 (+10%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1302 calculated?
We run LifeTech Scientific Corp through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$1.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. LifeTech Scientific Corp currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LifeTech Scientific Corp (1302)?
The closing price on Nov 13, 2026 was HK$1.55. Our model-based fair value is HK$1.70, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LifeTech Scientific Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$1.19 to HK$2.20) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of LifeTech Scientific Corp (1302) come from?
Earnings per share at LifeTech Scientific Corp grew 11.8 % a year from 2015 to 2025. Broken into its drivers: revenue per share +16.2 %, EBIT margin −5.3 %, tax rate +1.3 %, residual (interest, one-offs) +0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of LifeTech Scientific Corp

How large is the market capitalisation of LifeTech Scientific Corp (1302)?
The market capitalisation of LifeTech Scientific Corp is HK$6.8B (≈ $863M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LifeTech Scientific Corp (1302)?
The price-to-sales ratio of LifeTech Scientific Corp is 16.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of LifeTech Scientific Corp (1302)?
The net margin of LifeTech Scientific Corp is 10.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LifeTech Scientific Corp (1302)?
The return on equity (ROE) of LifeTech Scientific Corp is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LifeTech Scientific Corp (1302)?
On an EBIT basis the return on assets of LifeTech Scientific Corp is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LifeTech Scientific Corp (1302)?
The operating margin of LifeTech Scientific Corp is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LifeTech Scientific Corp (1302)?
Revenue at LifeTech Scientific Corp is down 11.2% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LifeTech Scientific Corp (1302)?
Earnings per share at LifeTech Scientific Corp are growing 413% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does LifeTech Scientific Corp (1302) hold?
LifeTech Scientific Corp holds more cash than debt, 765M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch LifeTech Scientific Corp in the live analysis

One click puts LifeTech Scientific Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.